



Rise of the SpatialOmics for Drug Development

Quarterly Newsletter/December 2020

Follow **ImaBiotech** : www.imabiotech.com

[www.linkedin.com/ImaBiotech](https://www.linkedin.com/company/ImaBiotech)

[www.youtube.com/ImaBiotech](https://www.youtube.com/channel/UC...)

To contact us : contact@imabiotech.com


With 2021 just around the corner, ImaBiotech wanted to share some exciting news about the company expansion of unique services. ImaBiotech is now offering **comprehensive image-based multi-omics profiling** to leverage your translation drug development effort. The company has developed a unique set of complementary techniques to measure and quantify the distribution of elements, metabolites, lipids, peptides, proteins and gene expression in a single sample to deliver the full picture of the diseases or the drug activity and patient response.

SERVICES

Introducing the ImaLink platform!

The imaging solution of choice from drug activity to patient responder

ImaLink platform can now detect and measure the distribution of every drugs and biomarkers (Proteins, RNAs, Lipids, Metabolites...) at the single cell resolution.




The **integration** of spatial information from multi-omics data quickly translate insights on disease biology, drug mechanism of action and identify the patient populations most likely to derive benefit from therapy in clinical trials and **accelerate** your drug development pipeline.

Learn More


INNOVATIONS

Introducing Testing Panel!



You can now browse ImaBiotech profiling service by exploring our unique testing panels in the tissue microenvironment!

- Explore by target
 - Over 100 proteins
 - Over 1500 RNAs
 - Over 500 metabolic and lipidomic signatures.
- Explore by pathway



MAPK Pathway

Proteins:

BRAF, EGFR, Phospho-c-RAF (S338), Phospho-INK (T183/Y185), Phospho-MEK1 (S217/S221), Phospho-p38 MAPK (T180/Y182), Phospho-p44/42 MAPK ERK1/2 (T202/Y204), pan-RAS, p44/42 MAPK ERK1/2, Phospho-p90 RSK (T359/S363)

RNAs:

AKT1, ANGPT1, ANGPT2, BAD, BCL2L1, CASP3, CD14, CHUK, CSF1, CSF1R, DUSP1, DUSP2, DUSP5, EGF, EGFR, FAS, FASLG, FGF13, FGF18, FGF9, FGFR1, FLNB, FLT1, GNG4, HRAS, IKBKB, IKBKG, IL1A, IL1B, IL1R2, KDR, KIT, MAP3K12, MAP3K5, MAP3K7, MAP3K_, MAPK10, MET, MYC, NFL, NFKB1, NFKB

- Explore by phenotype

- Immune exhaustion

- B-Cells, CD45, CD8 T Cell, Cytotoxic Cells, DC, exhausted CD8, Macrophages, Mast Cells, neutrophils, NK cells, T cells, Th1 cells, Treg.

- Immune activation status

- CD127, CD25, CD80, ICOS, PD-L2, CD40, CD44, CD2

- Explore by Therapeutic area

- Oncology
 - Immuno-Oncology
 - Neuroscience


You can also drop us a line for a customized pathway by describing the target of interest and our service contact will get back to you.

[Contact Us](#)

TECHNOLOGY CORNER

Focus on Single Cell Imaging!

ImaBiotech developed a technology that allows the identification of protein markers at **subcellular resolution** while preserving the information in tissue architecture to allow deep profiling of the tissue microenvironment.



Distribution and quantification of leucocytes, macrophages, T helper and Treg cell population. Cell populations interplays can further be correlated to new drug target discovery or drug response taking into account the heterogeneity of the microenvironment.

INTERVIEWS

Interview with Dr. Jonathan Stauber ImaBiotech Founder & CEO



How is ImaBiotech today?

Thanks to the involvement of our collaborators in France and in the USA and to our continuity plans, we have been able to maintain our activities during this Covid19 pandemic and reach our sponsor's expectations. The order book is filled! The company reinforced this year its leading position in spatial drug distribution and pharmacokinetics analysis offering to our pharma partners.

What inspired you to start offering a comprehensive multi-omics solution to your client?

Multi-omics analysis which takes advantages of technologies in transcriptomic, proteomic, metabolomics and other omics is the key to advancing precision medicine. Cells do not exist in isolation in the human body, and the interactions between different cell types and cell molecular heterogeneity in disease states carries significant information that multi-omics analysis can unlock in drug development effort.

What is your competitive advantage in the multi-omics service offering space?

In addition to abundance of molecules, our unique offering includes morphological observations and localization of bio-molecules. The simultaneous measuring of multiple modalities from the same anatomical area is a powerful tool to elucidate pathological condition related to cell heterogeneity and therefore resistance mechanism to treatment.

What can we expect from your teams in the near future?

Innovation is ImaBiotech's DNA and this is not antagonist to our service business. I always believe that investing in innovative technology is the right choice. With that in mind, you should expect to hear news in that sense in the near future specially in leading single cell molecular imaging analysis.

I would like to end by wishing everyone a joyous holiday season and a most prosperous and healthy New Year!



**CONTACT US FOR MORE INFORMATION ABOUT
NEXT LEVEL IMAGING AND SPATIALOMICS**